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Conclusions: Major bleeding is common after primary PCI for STEMI and associated
with increased mortality during 1 year follow-up. The CRUSADE bleeding risk score
underestimated the risk of major bleeding and therefore the use of this tool might be
limited in STEMI.
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Background: Red cell distribution width (RDW), a numerical measure of the variability
of the size of circulating erythrocytes, has been shown to be an independent predictor of
mortality in cardiovascular disease, and in patients undergoing PCI. The purpose of this
study was to determine if RDW is a prognostic marker of major post-PCI bleeding.
Methods: The study population included 4387 patients with coronary artery disease who
were subjected to PCI. The RDW was derived from a complete blood count (CBC) drawn
before PCI. Major bleeding was defined as hematocrit decrease15%, transfusion of2
units of packed red blood cells, gastrointestinal or intracerebral bleeding. Multivariable
logistic analysis of major in-hospital bleeding was performed using a logistic regression
model. Baseline characteristics associated with bleeding were included in the model.
Results: In 250 patients with a bleed, RDW was significantly higher than in the 4137
patients who did not bleed (14.4 	/ 2.1% vs 13.5 	/ 1.6%, p 0.001). On
multivariable analysis, after adjustment for known correlates of bleeding, RDW was a
significant predictor of bleeding (OR 1.14, 95% CI 1.05-1.23, p0.002). (Table 1)
Conclusions: RDW, an easily obtainable marker, has a strong independent linear
relationship with major post-procedure bleeding in patients undergoing PCI. These data
suggest that further investigation is necessary to determine the relationship of RDW and
bleeding post-PCI.
Independent Correlates of Major Bleeding Post PCI
Variable OR 95% CI p value
RDW 1.14 1.05–1.23 0.002
Male 0.47 0.34–0.64 0.001
BMI 0.97 0.94–1.0 0.021
IABP use 3.42 2.05–5.71 0.001
Cardiogenic Shock 2.28 1.2–4.34 0.012
Acute MI 2.19 1.42–3.38 0.001
Angiomax®(Bivalrudin) 0.53 0.37–0.77 0.001
Closure Device 0.66 0.48–0.90 0.01
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Background: Consensus guidelines recommend discontinuation of thienopyridine ther-
apy 5-7 days before planned coronary artery bypass graft (CABG) surgery to reduce
bleeding-related events. However, surgery is often performed within this time period to
reduce the risk of ischemic events. Evidence supporting the use of on-treatment platelet
reactivity testing before CABG is limited.
Methods: Patients undergoing CABG within 5 days of thienopyridine discontinuation
were prospectively enrolled from 08/2010 to 02/2012. On-treatment platelet reactivity
was measured with Verify Now (VN) P2Y12 assay, vasodilator stimulated phosphopro-
tein phosphorylation (VASP) and light transmittance aggregometry (LTA) with 5 and 20
M of ADP. The primary end point was in-hospital major bleeding (IHMB), defined as
bleeding intracranially, that associated with hemodynamic compromise, a hemoglobin
drop of 5 g/dl, or a hematocrit drop of 15%. The relation between platelet reactivity
value and IHMB was assessed with Wilcoxon rank-sum test; its relation with hematocrit
(Htc) drop was evaluated with Spearman correlation.
Results: The population consisted of 80 patients. IHMB occurred in 37 patients (46.3%).
VASP and LTA with 5 M or 20 M of ADP were associated with the primary endpoint
(IHMB). (Table) VN and VASP levels demonstrated an inverse correlation with the
degree of Htc drop after CABG (p0.002 and 0.041, respectively). A VASP platelet
reactivity index (PRI) of 50% is predictive of IHMB (p0.013), but a cut-off value of 230
P2Y12 reaction units (PRU) for VN is not (p0.26). Surgical related bleeding is not
predicted by platelet reactivity testing.
Major bleeding
present (Median [IQ
range])
Major bleeding
absent (Median [IQ
range]) p Value
Verify Now
(PRU)
198 [156–271] 221.5 [195–275] 0.093
VASP (PRI ) 55.2 [25–64] 62.5 [52.5–74.9] 0.004
LTA ADP 5M 39 [31.5–49] 49 [43–56] 0.002
LTA ADP 20M 48.5 [43–65.5] 65 [55–72] 0.002
Conclusions: On-treatment platelet reactivity testing with VASP or LTA 5 M or 20
M of ADP before CABG are able to predict the occurrence IHMB. A VASP PRI value
of 50% may indicate the need to postpone surgery for patients undergoing CABG
within 5 days of thienopyridine discontinuation.
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Background: Coronary no reflow is infrequent complications during percutanous
coronary intervention (PCI), however its impact on long term clinical outcome is not well
studied.
Methods: A total 1926 all comer patients (pts) including acute myocardial infarction
(MI) pts who underwent PCI with DESs were enrolled for this study. Study population
was divided into two groups; no reflow group (n50 pts) and non no reflow group
(n1876 pts). Angiographic at 6 months and clinical outcomes up to 24 months were
compared between the two groups.
Results: Baseline characteristics were similar between the two groups. The incidence of
angiographic no-reflow was in 2.6% (50/1926). At 6 months, no-reflow group had more
incidences of higher late loss. At 24 months clinical follow up, the no-reflow group had
worse clinical outcomes including higher cumulative incidence of total death, Q-MI and
major adverse cardiac events (MACEs, Table).
Conclusions: In the current study, despite of low incidence of no-reflow in general PCI
population, those patients had worse angiographic and clinical outcomes up to 24 months.
Special care should be exercised in this particular subset of pts during and after the
procedure.
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